AG˹ٷ

STOCK TITAN

Usana Health Sciences Inc SEC Filings

USNA NYSE

Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Deferred revenue from customer incentives, multi-currency sales in Asia, and product repurchase obligations turn each USANA annual report 10-K simplified into a dense read. If you’ve searched for �USANA SEC filings explained simply,� you already know how challenging it is to locate segment margins or wellness-product growth without spending hours in footnotes.

Stock Titan’s AI steps in with line-by-line summaries, highlighting what matters in every USANA quarterly earnings report 10-Q filing, tagging risk-factor changes, and alerting you whenever a board meeting triggers a disclosure. Our engine delivers USANA 8-K material events explained within minutes of hitting EDGAR, while interactive charts power quick USANA earnings report filing analysis. Need context on incentive-driven cash flows? Click once and you’re understanding USANA SEC documents with AI instead of decoding accounting jargon.

For governance watchers, real-time pop-ups surface USANA Form 4 insider transactions real-time, plus sortable tables of USANA executive stock transactions Form 4. Compensation analysts can dive into the USANA proxy statement executive compensation sections without losing focus—our AI extracts option awards and long-term bonus targets automatically. Whether you’re screening for �USANA insider trading Form 4 transactions� before earnings or reviewing nutritional segment trends, you’ll find every filing type�10-K, 10-Q, 8-K, Form 4, S-8, and more—updated the moment they post. Stock Titan turns complex disclosures into practical insight so you can act, not sift.

Rhea-AI Summary

Gilbert A. Fuller, a director of USANA Health Sciences Inc (USNA), reported a sale of 1,058 shares of common stock on 08/07/2025 at approximately $29.1014 per share. The Form 4 lists the transaction as a sale and shows 0 shares beneficially owned by Fuller following the reported transaction, with ownership held directly. The filing discloses the required Section 16 details for the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

USANA Health Sciences, Inc. (USNA) � Quarterly report (10-Q) for period ended June 28, 2025.

Key financials: Net sales were $235.8M for Q2 2025, up 10.8% y/y; six‑month net sales were $485.4M. Net earnings attributable to USANA were $9.7M for Q2 (Q2 2024: $10.4M) and $19.1M for six months (prior: $27.0M). Diluted EPS was $0.52 for the quarter and $1.01 for six months.

Material events and balance sheet highlights: the company completed a controlling acquisition of Hiya on December 23, 2024 for a final purchase price of $206,074, recognizing $127.3M of goodwill and $124.2M of intangibles (acquired). Cash and cash equivalents were $151.3M as of June 28, 2025 ($154.1M total cash, cash equivalents and restricted cash). Inventories increased to $83.3M. During the six months the company repurchased and retired 927 shares for $27.7M. A redeemable noncontrolling interest in Hiya totaled $54.5M. The Credit Facility provides up to $75.0M revolver capacity; outstanding balance was $0 at June 28, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Summary

USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.

  • Transaction date: 30 Jul 2025
  • Shares sold: 3,515 common shares
  • Sale price: $30.26 per share (approx. $106 k total proceeds)
  • Shares owned after sale: 9,260 (direct)

No derivative securities were reported. The filing was signed on 31 Jul 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Summary

USANA Health Sciences (USNA) filed a Form 144 indicating an insider’s intent to sell 3,515 common shares through Morgan Stanley Smith Barney on or after 30 Jul 2025. The shares have an aggregate market value of $106,364, based on the filing date, and represent roughly 0.02 % of the company’s 18.6 million shares outstanding.

The stock being sold was acquired as restricted-stock awards: 1,138 shares granted on 4 Feb 2022 and 2,377 shares granted on 6 Feb 2025. No prior insider sales were reported in the past three months, and the filer affirms possession of no undisclosed material adverse information.

The transaction is modest relative to USNA’s float and appears to be a routine liquidity event rather than a signal of fundamental change. Nevertheless, investors often monitor Form 144 filings for potential sentiment shifts among insiders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

USANA Health Sciences (USNA) � Form 4 filing

On 24-Jul-2025, CEO & President Jim Brown converted 2,190 previously granted restricted stock units (code “M�) into an equal number of common shares. To satisfy withholding taxes, 972 of those shares were automatically surrendered to the issuer at $32.09 per share (code “F�). The net effect is an increase of 1,218 directly held shares, bringing Brown’s direct common-stock ownership to 16,934. He also retains 160,878 unvested/derivative RSUs that will convert into common shares as they vest. No open-market purchases or sales occurred; all transactions were internal equity-compensation settlements. The filing does not disclose any broader corporate developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

USANA Health Sciences (USNA) Form 4 � Director Ding Xia reported routine equity transactions dated 24 Jul 2025.

  • Exercise of RSUs (Code M): 1,058 restricted stock units converted 1:1 into common shares, increasing direct holdings.
  • Tax‐withholding sale (Code F): 265 shares were surrendered at $32.09 to satisfy withholding obligations.
  • Post-transaction ownership: 5,337 common shares held directly and 3,172 unvested RSUs remain outstanding. RSUs vest 25 % on four quarterly dates between 24 Jul 2025 and 23 Apr 2026.

No purchase or sale of shares for investment purposes occurred; the net change (+793 shares) stems from normal equity compensation. No other directors or officers are listed, and there is no indication of material information affecting USNA’s operations or outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

USANA Health Sciences (USNA) Form 4: Director John Turman Fleming reported the automatic conversion of 1,058 Restricted Stock Units (RSUs) into an equal number of common shares on 24 Jul 2025 (transaction code M � derivative conversion). No cash price was paid at conversion.

Post-transaction holdings:

  • Common stock held directly: 5,258 shares (up from 4,200).
  • Unvested RSUs remaining: 3,172 units.

The RSU award vests in four equal tranches of 25% each on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. Fleming’s filing reflects the first vesting event. There was no open-market buying or selling; the transaction simply moves shares from derivative to common ownership, marginally increasing the director’s freely tradable stake.

Given the modest size relative to USNA’s ~19 million outstanding shares, the event is immaterial to corporate finances. It does, however, signal continued equity alignment between the director and shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Usana Health Sciences (USNA)?

The current stock price of Usana Health Sciences (USNA) is $32.24 as of August 22, 2025.

What is the market cap of Usana Health Sciences (USNA)?

The market cap of Usana Health Sciences (USNA) is approximately 568.6M.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Stock Data

568.62M
10.41M
42.93%
61.14%
4.03%
Packaged Foods
Medicinal Chemicals & Botanical Products
United States
SALT LAKE CITY